A Phase 1, Open-label, Dose-escalation Safety And Pharmacokinetic Study Of Mdv3100 In Patients With Castration-resistant Prostate Cancer

Trial Profile

A Phase 1, Open-label, Dose-escalation Safety And Pharmacokinetic Study Of Mdv3100 In Patients With Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 14 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top